AU2017388753A1 - Synthetic guide molecules, compositions and methods relating thereto - Google Patents
Synthetic guide molecules, compositions and methods relating thereto Download PDFInfo
- Publication number
- AU2017388753A1 AU2017388753A1 AU2017388753A AU2017388753A AU2017388753A1 AU 2017388753 A1 AU2017388753 A1 AU 2017388753A1 AU 2017388753 A AU2017388753 A AU 2017388753A AU 2017388753 A AU2017388753 A AU 2017388753A AU 2017388753 A1 AU2017388753 A1 AU 2017388753A1
- Authority
- AU
- Australia
- Prior art keywords
- linkage
- independently
- integer
- guide molecule
- inclusive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *[C@]1COC(COP(*)(I)=*)(CC2)OC2CC1 Chemical compound *[C@]1COC(COP(*)(I)=*)(CC2)OC2CC1 0.000 description 53
- LWHWIOSQFBECJW-DTIOYNMSSA-N CC(C)C[C@H](C1CCNC)C1=C Chemical compound CC(C)C[C@H](C1CCNC)C1=C LWHWIOSQFBECJW-DTIOYNMSSA-N 0.000 description 1
- IUIAIEOUWVORAT-UHFFFAOYSA-N CCC(CO)C(C(CBNC)O)O Chemical compound CCC(CO)C(C(CBNC)O)O IUIAIEOUWVORAT-UHFFFAOYSA-N 0.000 description 1
- XUXCFSOKUPDRFK-UHFFFAOYSA-O CCCCN1N(N)N(NNN2N3N(N4N5N(NC)N4CC)N5N3N2NN[NH3+])N1CC Chemical compound CCCCN1N(N)N(NNN2N3N(N4N5N(NC)N4CC)N5N3N2NN[NH3+])N1CC XUXCFSOKUPDRFK-UHFFFAOYSA-O 0.000 description 1
- SYVVPGIYIOWVHX-UHFFFAOYSA-N COC(C1OF)C(CO)(CC2)OC12I Chemical compound COC(C1OF)C(CO)(CC2)OC12I SYVVPGIYIOWVHX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2024205204A AU2024205204A1 (en) | 2016-12-30 | 2024-07-30 | Synthetic guide molecules, compositions and methods relating thereto |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662441046P | 2016-12-30 | 2016-12-30 | |
| US62/441,046 | 2016-12-30 | ||
| US201762492001P | 2017-04-28 | 2017-04-28 | |
| US62/492,001 | 2017-04-28 | ||
| PCT/US2017/069019 WO2018126176A1 (en) | 2016-12-30 | 2017-12-29 | Synthetic guide molecules, compositions and methods relating thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024205204A Division AU2024205204A1 (en) | 2016-12-30 | 2024-07-30 | Synthetic guide molecules, compositions and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017388753A1 true AU2017388753A1 (en) | 2019-07-11 |
Family
ID=61187807
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017388753A Abandoned AU2017388753A1 (en) | 2016-12-30 | 2017-12-29 | Synthetic guide molecules, compositions and methods relating thereto |
| AU2024205204A Pending AU2024205204A1 (en) | 2016-12-30 | 2024-07-30 | Synthetic guide molecules, compositions and methods relating thereto |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024205204A Pending AU2024205204A1 (en) | 2016-12-30 | 2024-07-30 | Synthetic guide molecules, compositions and methods relating thereto |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230111575A1 (https=) |
| EP (1) | EP3565895A1 (https=) |
| JP (3) | JP7167029B2 (https=) |
| KR (2) | KR102758180B1 (https=) |
| CN (2) | CN118345072A (https=) |
| AU (2) | AU2017388753A1 (https=) |
| CA (1) | CA3048434A1 (https=) |
| MX (1) | MX420023B (https=) |
| WO (1) | WO2018126176A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015134812A1 (en) | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
| US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| WO2015138510A1 (en) | 2014-03-10 | 2015-09-17 | Editas Medicine., Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
| US11242525B2 (en) | 2014-03-26 | 2022-02-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating sickle cell disease |
| US12460231B2 (en) | 2014-04-02 | 2025-11-04 | Editas Medicine, Inc. | Crispr/CAS-related methods and compositions for treating primary open angle glaucoma |
| CA2982966C (en) | 2015-04-24 | 2024-02-20 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
| WO2017165862A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018026976A1 (en) | 2016-08-02 | 2018-02-08 | Editas Medicine, Inc. | Compositions and methods for treating cep290 associated disease |
| US10941402B2 (en) | 2016-09-01 | 2021-03-09 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded RNA-editing oligonucleotides |
| US11274300B2 (en) | 2017-01-19 | 2022-03-15 | Proqr Therapeutics Ii B.V. | Oligonucleotide complexes for use in RNA editing |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
| EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| US20190076814A1 (en) | 2017-09-11 | 2019-03-14 | Synthego Corporation | Biopolymer synthesis system and method |
| WO2019178426A1 (en) | 2018-03-14 | 2019-09-19 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| KR20210045360A (ko) | 2018-05-16 | 2021-04-26 | 신테고 코포레이션 | 가이드 rna 설계 및 사용을 위한 방법 및 시스템 |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| GB201901873D0 (en) * | 2019-02-11 | 2019-04-03 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for nucleic acid editing |
| CN114423865A (zh) | 2019-05-23 | 2022-04-29 | Vor生物制药股份有限公司 | Cd33修饰的组合物和方法 |
| AU2020336211A1 (en) | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CD123 modification |
| US20220290160A1 (en) | 2019-08-28 | 2022-09-15 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| US20240110189A1 (en) | 2020-08-28 | 2024-04-04 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| US20240238344A1 (en) | 2020-08-28 | 2024-07-18 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| JP2023541457A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３８修飾のための化合物および方法 |
| WO2022056459A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd5 modification |
| WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
| US20230364146A1 (en) | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| CA3199623A1 (en) | 2020-10-27 | 2022-05-05 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| JP2023550355A (ja) | 2020-11-13 | 2023-12-01 | ブイオーアール バイオファーマ インコーポレーテッド | キメラ抗原受容体を発現する遺伝子操作された細胞に関連する方法および組成物 |
| WO2022147347A1 (en) | 2020-12-31 | 2022-07-07 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
| US20240200059A1 (en) | 2021-04-09 | 2024-06-20 | Vor Biopharma Inc. | Photocleavable guide rnas and methods of use thereof |
| US20240384304A1 (en) | 2021-07-06 | 2024-11-21 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| AU2022324093A1 (en) | 2021-08-02 | 2024-02-08 | Vor Biopharma Inc. | Compositions and methods for gene modification |
| US20240417755A1 (en) | 2021-09-27 | 2024-12-19 | Vor Biopharma Inc. | Fusion polypeptides for genetic editing and methods of use thereof |
| CA3236152A1 (en) | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
| US20250179531A1 (en) | 2022-02-25 | 2025-06-05 | Vor Biopharma Inc. | Compositions and methods for homology-directed repair gene modification |
| US20250295695A1 (en) | 2022-04-04 | 2025-09-25 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| EP4623081A2 (en) * | 2022-11-23 | 2025-10-01 | Prime Medicine, Inc. | Split synthesis of long rnas |
| WO2024168312A1 (en) | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
| WO2025006216A2 (en) * | 2023-06-29 | 2025-01-02 | Synthego Corporation | Methods and systems for automated fraction selection in nucleic acid manufacturing |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| WO2025194138A1 (en) | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | St1cas9 compositions and methods for modulating a genome |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX357240B (es) * | 2011-10-10 | 2018-06-29 | Kmt Waterjet Systems Inc | Conexión de alta presion sin juntas. |
| AU2014346559B2 (en) * | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
| WO2015138510A1 (en) | 2014-03-10 | 2015-09-17 | Editas Medicine., Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
| US11242525B2 (en) * | 2014-03-26 | 2022-02-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating sickle cell disease |
| WO2016057951A2 (en) * | 2014-10-09 | 2016-04-14 | Life Technologies Corporation | Crispr oligonucleotides and gene editing |
| CA2963820A1 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| US10059940B2 (en) * | 2015-01-27 | 2018-08-28 | Minghong Zhong | Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents |
| EP3280803B1 (en) * | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| CA2982966C (en) * | 2015-04-24 | 2024-02-20 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
| ES2835861T5 (en) * | 2015-05-08 | 2025-02-18 | Childrens Medical Ct Corp | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
| CN107709555A (zh) * | 2015-05-15 | 2018-02-16 | 达尔马科恩有限公司 | 用于Cas9介导的基因编辑的合成的单向导RNA |
| US11518994B2 (en) * | 2016-01-30 | 2022-12-06 | Bonac Corporation | Artificial single guide RNA and use thereof |
| EP3443088B1 (en) | 2016-04-13 | 2024-09-18 | Editas Medicine, Inc. | Grna fusion molecules, gene editing systems, and methods of use thereof |
-
2017
- 2017-12-29 AU AU2017388753A patent/AU2017388753A1/en not_active Abandoned
- 2017-12-29 MX MX2019007750A patent/MX420023B/es unknown
- 2017-12-29 CN CN202410342599.0A patent/CN118345072A/zh active Pending
- 2017-12-29 JP JP2019535879A patent/JP7167029B2/ja active Active
- 2017-12-29 KR KR1020237043357A patent/KR102758180B1/ko active Active
- 2017-12-29 WO PCT/US2017/069019 patent/WO2018126176A1/en not_active Ceased
- 2017-12-29 KR KR1020197022278A patent/KR102618864B1/ko active Active
- 2017-12-29 US US16/474,198 patent/US20230111575A1/en active Pending
- 2017-12-29 CA CA3048434A patent/CA3048434A1/en active Pending
- 2017-12-29 EP EP17840468.7A patent/EP3565895A1/en active Pending
- 2017-12-29 CN CN201780085248.4A patent/CN110249052B/zh active Active
-
2022
- 2022-09-26 JP JP2022152461A patent/JP7610559B2/ja active Active
-
2024
- 2024-07-30 AU AU2024205204A patent/AU2024205204A1/en active Pending
- 2024-11-08 JP JP2024195755A patent/JP2025016776A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025016776A (ja) | 2025-02-04 |
| AU2024205204A1 (en) | 2024-09-05 |
| MX420023B (es) | 2025-01-14 |
| JP2022173349A (ja) | 2022-11-18 |
| KR102758180B1 (ko) | 2025-01-23 |
| JP2020503049A (ja) | 2020-01-30 |
| US20230111575A1 (en) | 2023-04-13 |
| WO2018126176A1 (en) | 2018-07-05 |
| JP7610559B2 (ja) | 2025-01-08 |
| MX2019007750A (es) | 2019-10-15 |
| EP3565895A1 (en) | 2019-11-13 |
| KR20230175330A (ko) | 2023-12-29 |
| CN110249052B (zh) | 2024-04-12 |
| CN118345072A (zh) | 2024-07-16 |
| KR102618864B1 (ko) | 2024-01-02 |
| KR20190110554A (ko) | 2019-09-30 |
| JP7167029B2 (ja) | 2022-11-08 |
| CN110249052A (zh) | 2019-09-17 |
| CA3048434A1 (en) | 2018-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7610559B2 (ja) | 合成ガイド分子、それに関連する組成物および方法 | |
| US12264331B2 (en) | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA | |
| US12049651B2 (en) | Cas9 fusion molecules, gene editing systems, and methods of use thereof | |
| US20190300872A1 (en) | Improved Methods of Genome Editing with and without Programmable Nucleases | |
| CA2969464A1 (en) | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | |
| US12338436B2 (en) | Synthetic guide molecules, compositions and methods relating thereto | |
| NZ795956A (en) | Synthetic guide molecules, compositions and methods relating thereto | |
| US20260083861A1 (en) | Crispr-related methods and compositions targeting cd70 expression | |
| NZ754735A (en) | Synthetic guide molecules, compositions and methods relating thereto | |
| WO2025227064A1 (en) | Genomic editing methods to treat cardiovascular disease, and compositions for use in practicing the same | |
| NZ795268A (en) | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |